



## Torrent – Recall of Valsartan-Containing Products

- On August 21, 2018, the [FDA announced](#) an update to the voluntary, consumer-level recall of Torrent's [amlodipine/valsartan/hydrochlorothiazide \(HCTZ\)](#), [amlodipine/valsartan](#) and [valsartan](#) tablets due to the presence of an impurity, N-nitrosodimethylamine (NDMA).
- From the initial [FDA announcement](#) on August 17, 2018, the recall has been expanded to include all lots of amlodipine/valsartan/HCTZ, amlodipine/valsartan, and valsartan tablets.
- The recalled valsartan-containing tablets were distributed nationwide.

Product Description	NDC#	Lot#
Amlodipine/valsartan/HCTZ 10 mg/320 mg/25 mg	13668-325-30	All unexpired lots
Amlodipine/valsartan/HCTZ 10 mg/160 mg/25 mg	13668-328-30	
Amlodipine/valsartan/HCTZ 5 mg/160 mg/12.5 mg	13668-326-30	
Amlodipine/valsartan/HCTZ 10 mg/160 mg/12.5 mg	13668-327-30	
Amlodipine/valsartan/HCTZ 5 mg/160 mg/25 mg	13668-329-30	
Amlodipine/valsartan 5 mg/160 mg	13668-207-30	
Amlodipine/valsartan 10 mg/160 mg	13668-206-30	
Amlodipine/valsartan 10 mg/320 mg	13668-204-30	
Amlodipine/valsartan 5 mg/320 mg	13668-205-30	
Valsartan 160 mg	13668-069-90	
Valsartan 320 mg	13668-070-90	
Valsartan 80 mg	13668-068-90	

- Valsartan is used to control high blood pressure and for the treatment of heart failure. In combination with amlodipine plus HCTZ or in combination with amlodipine alone, it is used to control high blood pressure.
- Consumers should contact their healthcare provider for further guidance and potential change of treatment before they stop taking their valsartan-containing prescription. Pharmacies and healthcare facilities that have the recalled product should stop using and dispensing the product immediately.
- Patients with questions regarding this recall can contact Torrent at **1-800-912-9561**. Patients should contact their healthcare provider if they have experienced any problems that might be related to taking or using the recalled valsartan-containing prescription.
- On July 13th, the [FDA initiated](#) a series of announcements regarding the recall of certain batches of valsartan and valsartan-HCTZ tablets because of unacceptable levels of NDMA.
- The FDA continues to maintain a [list of drugs included in the recall](#) and a [list of drugs not included in the recall](#). These lists were last updated on August 20, 2018. Note that not all of the recalled Torrent products are included in the list of drugs included in the recall.

Continued . . .

- Prior Clinical News Summaries summarizing the valsartan recalls were released [July 17<sup>th</sup>](#), [July 19<sup>th</sup>](#), [July 27<sup>th</sup>](#), [July 30<sup>th</sup>](#), [August 3<sup>rd</sup>](#), [August 9<sup>th</sup>](#), [August 14<sup>th</sup>](#), and [August 20<sup>th</sup>](#).



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.